Larinate® 60mg for injection

Ipca

Legend
Product category

  • Severe malaria treatment (artesunate for injection)
Therapeutic indication

  • Treatment of severe malaria caused by the parasite P. falciparum, to be followed by a full course of ACT
Dosing

  • At least 3 injections within 1 day during critical phase
Efficacy

  • 92% survival vs 88% survival with quinine in African children

  • Coma duration, convulsions, and hypoglycaemia significantly lower with artesunate compared to quinine
Key features

  • Increased global supply for artesunate for injection

  • Cost per disability-adjusted life year (DALY) averted: US$ 3.8

  • Three-year shelf life
Challenges

  • Potential for delayed haemolytic anaemia

  • Continued use of quinine or artemether for injection
Status

  • WHO prequalification in 2018

  • Approved in 15 countries; 8.9 million Larinate® vials shipped since prequalification
Next milestone

  • Simplified injectable artesunate two-vial to be developed for WHO prequalification review

  • Additional country registrations
MMV Project Director

  • Hans Rietveld